Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ajulemic acid - Corbus Pharmaceuticals

Drug Profile

Ajulemic acid - Corbus Pharmaceuticals

Alternative Names: Anabasum; CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Lenabasum; Resunab

Latest Information Update: 10 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals; University of Erlangen-Nuremberg; University of Siena
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Antirheumatics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Dermatomyositis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dermatomyositis; Systemic scleroderma
  • Phase II Cystic fibrosis; Systemic lupus erythematosus
  • Phase I Inflammation
  • Preclinical Pulmonary fibrosis; Rheumatoid arthritis
  • Discontinued Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning

Most Recent Events

  • 04 Jan 2019 Ajulemic acid (Lanabasum) licensed to Kaken Pharmaceutical for development and marketing for Systemic scleroderma and Dermatomyositis in Japan
  • 18 Dec 2018 Corbus Pharmaceuticals has patent protection for the use of pharmaceutical compositions comprising ajulemic acid in USA
  • 17 Dec 2018 Phase-III clinical trials in Dermatomyositis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top